In order to evaluate the therapeutic efficacy of a selective P2X7-targeting compound in an experimental model of α-sarcoglycanopathy, we treated four-week-old male Sgca knockout mice (also termed Sgca-null) mice with A438079, a specific antagonist of P2X7 [26]. This evidence concerns the gene SGCA and sarcoglycanopathy.